ClawHub

Alexion

v1.0.1

Specializes in rare disease drugs using complement inhibition, building a $10B franchise led by Soliris and acquired by AstraZeneca in 2021.

⭐ 0· 95·1 current·1 all-time
by@hanxueyuan

Install

OpenClaw Prompt Flow

Install with OpenClaw

Best for remote or guided setup. Copy the exact prompt, then paste it into OpenClaw for hanxueyuan/alexion.

Previewing Install & Setup.
Prompt PreviewInstall & Setup
Install the skill "Alexion" (hanxueyuan/alexion) from ClawHub.
Skill page: https://clawhub.ai/hanxueyuan/alexion
Keep the work scoped to this skill only.
After install, inspect the skill metadata and help me finish setup.
Use only the metadata you can verify from ClawHub; do not invent missing requirements.
Ask before making any broader environment changes.

Command Line

CLI Commands

Use the direct CLI path if you want to install manually and keep every step visible.

OpenClaw CLI

Bare skill slug

openclaw skills install alexion

ClawHub CLI

Package manager switcher

npx clawhub@latest install alexion
Security Scan
VirusTotalVirusTotal
Benign
View report →
OpenClawOpenClaw
Benign
high confidence
✓
Purpose & Capability
Skill name and description (rare-disease/complement inhibition specialist) match the SKILL.md content (timeline, business model, facts). It does not request unrelated resources or capabilities.
✓
Instruction Scope
SKILL.md contains factual/background content and a short read_when list — it does not instruct the agent to read files, access environment variables, call external endpoints, or perform actions outside summarizing/answering on the topic.
✓
Install Mechanism
No install spec and no code files are present (instruction-only). Nothing is written to disk or downloaded, minimizing installation risk.
✓
Credentials
No environment variables, credentials, or config paths are required. The skill does not ask for secrets or unrelated tokens.
✓
Persistence & Privilege
always is false and the skill is user-invocable; autonomous model invocation is allowed (platform default) but the skill has no capabilities that would expand risk if invoked autonomously.
Assessment
This skill is low-risk and appears to be a content-only reference about Alexion and complement inhibitors. Before installing, note the source is unknown — verify any clinical, financial, or pricing claims against primary sources if you plan to act on them. Monitor future updates: if a later version adds installs, network access, or required credentials, re-evaluate before trusting it. If you need verified clinical guidance, prefer official publications or regulatory documents rather than a third-party skill summary.

Like a lobster shell, security has layers — review code before you run it.

latestvk9735z2tpdyz43vwcp8a0hdp6d85d1nn
95downloads
0stars
2versions
Updated 5d ago
v1.0.1
MIT-0
@hanxueyuan
latest
Download

Alexion — 罕见病药物专家

历史时间线

  • 1992: Leonard Bell 在康涅狄格创立 Alexion
  • 1990s-2000s: 专注于补体系统研究
  • 2007: Soliris（依库珠单抗）获批，首个补体抑制剂
  • 2011-2019: Soliris 成为全球最昂贵药物之一（年定价 $70 万+）
  • 2019: Ultomiris 获批——Soliris 的升级版
  • 2021: AstraZeneca 以 $390 亿收购 Alexion
  • 2023: 补体抑制剂组合贡献 AstraZeneca 约 $60 亿营收

商业模式

罕见病药物——超高定价 + 长生命周期。Soliris 覆盖 PNH、aHUS 等罕见适应症，每个患者年均治疗费用 $70-80 万。

护城河分析

补体抑制剂领域的先发优势——10+ 年的独占专利。罕见病患者群体小但付费意愿极强（保险公司覆盖）。AstraZeneca 的渠道整合加速了全球扩张。

关键数据

  • 被 AstraZeneca 以 $390 亿收购
  • Soliris 累计营收超 $300 亿
  • Ultomiris 年营收约 $40 亿
  • 全球约 2 万名患者受益

有趣事实

Soliris 上市时的年定价超过 $70 万美元，被称为"全球最贵药物"。但其临床价值巨大——将 PNH 患者的死亡率从 50% 降至接近零。Alexion 的创始人 Bell 曾说："我们不是在高价卖药，我们是在卖生命。"

Comments

Loading comments...